Substance use disorders and COVID-19: An analysis of nation-wide Veterans Health Administration electronic health records. (1st May 2022)

• Record Type: Journal Article
• Authors: Hasin, Deborah S.; Fink, David S.; Olfson, Mark; Saxon, Andrew J.; Malte, Carol; Keyes, Katherine M.; Gradus, Jaimie L.; Cerdá, Magdalena; Maynard, Charles C.; Keyhani, Salomeh; Martins, Silvia S.; Livne, Ofir; Mannes, Zachary L.; Sherman, Scott E.; Wall, Melanie M.
• Is Part Of: Drug and alcohol dependence. Volume 234(2022)
• Publication Date: 2022-05-01
• Subjects: COVID-19 -- Substance use disorder -- Veterans Health Administration -- Hospitalization -- Mortality; Drug abuse -- Periodicals; Alcoholism -- Periodicals; 616.86
• DOI: 10.1016/j.drugalcdep.2022.109383
• Languages: English
• ISSNs: 0376-8716

Abstract

Abstract: Background: Substance use disorders (SUD) elevate the risk for COVID-19 hospitalization, but studies are inconsistent on the relationship of SUD to COVID-19 mortality. Methods: Veterans Health Administration (VHA) patients treated in 2019 and evaluated in 2020 for COVID-19 (n=5, 556, 315), of whom 62, 303 (1.1%) tested positive for COVID-19 (COVID-19+). Outcomes were COVID-19+ by 11/01/20, hospitalization, ICU admission, or death within 60 days of a positive test. Main predictors were any ICD-10-CM SUDs, with substance-specific SUDs (cannabis, cocaine, opioid, stimulant, sedative) explored individually. Logistic regression produced unadjusted and covariate-adjusted odds ratios (OR; aOR). Results: Among COVID-19+ patients, 19.25% were hospitalized, 7.71% admitted to ICU, and 5.84% died. In unadjusted models, any SUD and all substance-specific SUDs except cannabis use disorder were associated with COVID-19+(ORs=1.06–1.85); adjusted models produced similar results. Any SUD and all substance-specific SUDs were associated with hospitalization (aORs: 1.24–1.91). Any SUD, cocaine and opioid disorder were associated with ICU admission in unadjusted but not adjusted models. Any SUD, cannabis, cocaine, and stimulant disorders were inversely associated with mortality in unadjusted models (OR=0.27–0.46). After adjustment, associations with mortality were no longer significant. In ad hoc analyses, adjusted odds of mortality were lower among the 49.9% of COVID-19+ patients with SUD who had SUD treatment in 2019, but not among those without such treatment. Conclusions: In VHA patients, SUDs are associated with COVID-19 hospitalization but not COVID-19 mortality. SUD treatment may provide closer monitoring of care, ensuring that these patients received needed medical attention, enabling them to ultimately survive serious illness. Highlights: In VHA patients, substance use disorders (SUD) predict COVID-19 hospitalization. In VHA patients, SUD do not predict COVID-19 mortality. SUD treatment may protect against COVID-19 mortality via close monitoring of care.